Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements.

doi:10.1158/1078-0432.CCR-11-0563

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Apr 2012

Hayes D Neil, Lucas Amy S, Tanvetyanon Tawee, Krzyzanowska Monika K, Chung Christine H, Murphy Barbara A, Gilbert Jill, Mehra Ranee, Moore Dominic T, Sheikh Arif, Hoskins Janelle, Hayward Michele C, Zhao Ni, O'Connor Wendi, Weck Karen E, Cohen Roger B, Cohen Ezra E W

Abstract excerpt

PURPOSE: A multicenter, open-label, phase II trial was conducted to evaluate the efficacy, safety, and tolerability of selumetinib in iodine-refractory papillary thyroid cancer (IRPTC). EXPERIMENTAL DESIGN: Patients with advanced IRPTC with or without follicular elements and documented disease progression within the preceding 12 months were eligible to receive selumetinib at a dose of 100 mg twice daily. The...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma, Follicular

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Benzimidazoles

Share to Carcinoma, Papillary

Share to Diarrhea

Share to Exanthema

Share to Fatigue

Share to Iodine Radioisotopes

Share to Thyroid Cancer, Papillary

Source

Open in PubMed Open full text

Identifiers

PMID: 22241789
DOI: 10.1158/1078-0432.CCR-11-0563
PMCID: PMC5157199

Genes

BRAF
HRAS
NRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements.PMID 22241789Read ↗

Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.Semantic proximity Read ↗

Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer.Semantic proximity Read ↗

Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.Semantic proximity Read ↗

Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.Semantic proximity Read ↗

Selpercatinib in the treatment of thyroid cancer.Semantic proximity Read ↗

Do BRAFV600E mutation and sodium-iodide symporter expression affect the response to radioactive iodine therapy in patients with papillary thyroid carcinoma?Semantic proximity Read ↗

Recent advances in the use of tyrosine kinase inhibitors against thyroid cancer.Semantic proximity Read ↗

Vemurafenib Active in Iodine-Refractory Thyroid Cancer.Semantic proximity Read ↗

BRAF inhibitors: experience in thyroid cancer and general review of toxicity.Semantic proximity Read ↗

Phase 3 Trial of Selpercatinib in Advanced RET -Mutant Medullary Thyroid CancerSemantic proximity Read ↗

MAPK pathway inhibitors enhance radioiodine sensitivity in anaplastic thyroid carcinoma through promoting NIS expression and ARF4-mediated NIS membrane transportSemantic proximity Read ↗

Libretto-531: A Phase III Study of Selpercatinib in Multikinase Inhibitor-Naïve RET -Mutant Medullary Thyroid CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.